270 related articles for article (PubMed ID: 6508321)
1. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells].
Ishida N; Saito M; Nanjo M
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2681-90. PubMed ID: 6508321
[TBL] [Abstract][Full Text] [Related]
2. Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.
Saito M; Ichimura O; Kataoka M; Moriya Y; Ueno K; Sugawara Y; Nanjo M; Ishida N
Cancer Immunol Immunother; 1986; 22(3):161-8. PubMed ID: 2425968
[TBL] [Abstract][Full Text] [Related]
3. [Combined effect of intraperitoneally administered OK-432 and recombinant interleukin (rIL-2) against mouse tumors].
Fujioka T; Shiraishi M; Tanji S; Koike H; Kumagai K; Kubo T; Ohhori T
Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):948-56. PubMed ID: 2789265
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
5. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice.
Saito M; Nanjo M; Kataoka M; Moriya Y; Sugawara Y; Yoshida T; Ishida N
Cancer Res; 1988 Aug; 48(15):4163-7. PubMed ID: 3390809
[TBL] [Abstract][Full Text] [Related]
6. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432.
Oshimi K; Kano S; Takaku F; Okumura K
J Natl Cancer Inst; 1980 Dec; 65(6):1265-9. PubMed ID: 7001124
[TBL] [Abstract][Full Text] [Related]
8. [Successful adoptive immunotherapy with OK432-inducible activated natural killer cells on tumor-bearing mice].
Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K
Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2546-55. PubMed ID: 2614190
[TBL] [Abstract][Full Text] [Related]
9. Augmentation by OK-432 of generation of culture-induced killer cells.
Ujiie T
Jpn J Exp Med; 1987 Jun; 57(3):153-61. PubMed ID: 3682231
[TBL] [Abstract][Full Text] [Related]
10. [Differences in the immunostimulatory activity and antitumor therapeutic effect of OK-432 and N-CWS].
Mizushima Y; Iwata M; Sato M; Hirata H; Takashima A; Yano S
Gan To Kagaku Ryoho; 1986 Jul; 13(7):2404-10. PubMed ID: 3729493
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). II. Analysis of the cytotoxic lymphocytes induced by OK-432 injection into tumor-bearing F344 rats.
Fukui H; Reynolds CW
J Natl Cancer Inst; 1987 Nov; 79(5):1019-24. PubMed ID: 3500354
[TBL] [Abstract][Full Text] [Related]
12. Induction and persistence in vivo of NK/LAK activity by a mannoprotein component of Candida albicans cell wall.
Scaringi L; Cornacchione P; Rosati E; Fettucciari K; Rossi R; Marconi P
Cell Immunol; 1994 May; 155(2):265-82. PubMed ID: 8181065
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of purified adherent lymphokine-activated killer cells in mice.
Gunji Y; Vujanovic NL; Hiserodt JC; Herberman RB; Gorelik E
J Immunol; 1989 Mar; 142(5):1748-54. PubMed ID: 2783950
[TBL] [Abstract][Full Text] [Related]
14. Induction of antitumor L3T4-positive T cells by OK-432 at tumor sites in mice.
Moriya Y; Sato H; Ito K; Saito M; Yoshida T; Ishida N
Cancer Immunol Immunother; 1993; 36(4):245-50. PubMed ID: 8094999
[TBL] [Abstract][Full Text] [Related]
15. [Anticancer effects of OK-432 (2). Anticancer actions of M phi activated by OK-432].
Saito M; Aonuma E; Noda T; Nakadate I; Nanjo M; Ebina T; Ishida N
Gan To Kagaku Ryoho; 1983 May; 10(5):1363-71. PubMed ID: 6870302
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
Ujiie T
Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
[TBL] [Abstract][Full Text] [Related]
17. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
[TBL] [Abstract][Full Text] [Related]
18. [Immunobiological studies of interferon-alpha A/D in comparison with a streptococcal preparation, OK-432].
Mizushima Y; Hirata H; Sakamoto K; Sato M; Morikage T; Maruyama M; Sasaki K; Yano S
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2710-5. PubMed ID: 3631971
[TBL] [Abstract][Full Text] [Related]
19. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.
Hayashi Y; Torisu M
Surgery; 1990 Jan; 107(1):74-84. PubMed ID: 2404351
[TBL] [Abstract][Full Text] [Related]
20. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells].
Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
